텔라닥 헬스(Teladoc Health, Inc.)는 미국 내는 물론 국제적으로도 개인에게 원격 의료 서비스를 제공합니다. 이들의 광범위한 솔루션은 일상적이고 급성적인 질환부터 당뇨병, 고혈압, 만성 ...
텔라독 헬스(TDOC) 주식은 다양한 밸류에이션 점검 결과 과소평가된 것으로 보이며, 할인현금흐름(DCF) 모델은 내재가치 대비 39.9% 할인 요인을 시사합니다. 5년 동안 93.9%에 이르는 주가 하락과 순손실 이력에도 불구하고, 보험 보장 확대와 월마트 파트너십이 향후 성장에 동력이 될 수 있습니다. 현재 시장은 매출(Price/Sales) 기준에 대해 큰 폭의 할인율을 적용하고 있는데, 이는 회사가 지속 가능한 수익성을 입증할 수 있다면 밸류에이션이 재평가(리레이팅)될 잠재력을 의미합니다.
텔라독 헬스(TDOC)는 2026년 6월 말에 러셀 성장 및 소형주 관련 여러 지수에서 제외됐습니다. 이는 단기 매출 전망이 정체돼 있고, 사용자당 평균 매출에 대한 압력이 커졌기 때문입니다. 이번 조치는 회사가 월마트와의 파트너십 같은 협력을 통해 매출을 안정화하려는 노력에도 불구하고, 투자자들이 성장 궤적에 대해 우려하고 있음을 보여줍니다. 해당 기사는 이러한 난관 속에서 텔라독의 향후 성장 잠재력에 대한 투자자들의 믿음을 다시 점검하도록 촉구합니다.
텔라독 헬스는 내셔널 농구 선수 협회(NBPA)와 다년 계약을 체결해, 협회의 선호 가상 1차 진료 제공자로 자리매김합니다. 이번 파트너십을 통해 현재 및 은퇴한 NBA 선수와 그 가족들은 텔라독의 포괄적인 가상 진료 서비스—긴급 진료, 정신 건강, 예방 검진—를 이용할 수 있습니다. 양측 조직은 일정이 빡빡한 개인들을 위한 유연하고 접근 가능한 의료의 중요성을 강조합니다.
Teladoc Health (TDOC)는 최근 성장 궤적에 대한 우려로 인해 여러 러셀 성장 및 소형주 지수에서 제외됐습니다. 여기에는 단기 매출 전망의 정체와 사용자 매출에 가해지는 압력이 포함됩니다. 이런 전개는 특히 월마트와의 파트너십 같은 이니셔티브를 통해 텔라독의 매출과 마진을 안정화하려는 노력에 대한 면밀한 관찰을 한층 강화합니다. 해당 기사는 이번 지수 편출과, 텔라독의 밸류에이션에 대한 애널리스트들의 관점이 엇갈리는 상황을 고려할 때 투자자들이 텔라독의 향후 전망을 다시 평가하도록 촉구합니다.
텔레독 헬스, Inc.의 평균 주가 목표가가 20명의 애널리스트 추정치를 바탕으로 7.40달러에서 7.47달러로 상향되었습니다. 목표 범위는 주당 5달러~10.50달러입니다. 이번 업데이트된 목표가는 7월 6일 종가 기준 약 20% 하락 가능성을 시사합니다. TDOC에 대한 컨센서스 평가는 26명의 애널리스트 가운데 "보유(Hold)"로 유지됩니다.
텔라독 헬스(TDOC) 주식은 다양한 밸류에이션 점검 결과 과소평가된 것으로 보이며, 할인현금흐름(DCF) 모델은 내재가치 대비 39.9% 할인 요인을 시사합니다. 5년 동안 93.9%에 이르는 주가 하락과 순손실 이력에도 불구하고, 보험 보장 확대와 월마트 파트너십이 향후 성장에 동력이 될 수 있습니다. 현재 시장은 매출(Price/Sales) 기준에 대해 큰 폭의 할인율을 적용하고 있는데, 이는 회사가 지속 가능한 수익성을 입증할 수 있다면 밸류에이션이 재평가(리레이팅)될 잠재력을 의미합니다.
텔라독 헬스(TDOC)는 2026년 6월 말에 러셀 성장 및 소형주 관련 여러 지수에서 제외됐습니다. 이는 단기 매출 전망이 정체돼 있고, 사용자당 평균 매출에 대한 압력이 커졌기 때문입니다. 이번 조치는 회사가 월마트와의 파트너십 같은 협력을 통해 매출을 안정화하려는 노력에도 불구하고, 투자자들이 성장 궤적에 대해 우려하고 있음을 보여줍니다. 해당 기사는 이러한 난관 속에서 텔라독의 향후 성장 잠재력에 대한 투자자들의 믿음을 다시 점검하도록 촉구합니다.
텔라독 헬스는 내셔널 농구 선수 협회(NBPA)와 다년 계약을 체결해, 협회의 선호 가상 1차 진료 제공자로 자리매김합니다. 이번 파트너십을 통해 현재 및 은퇴한 NBA 선수와 그 가족들은 텔라독의 포괄적인 가상 진료 서비스—긴급 진료, 정신 건강, 예방 검진—를 이용할 수 있습니다. 양측 조직은 일정이 빡빡한 개인들을 위한 유연하고 접근 가능한 의료의 중요성을 강조합니다.
Teladoc Health (TDOC)는 최근 성장 궤적에 대한 우려로 인해 여러 러셀 성장 및 소형주 지수에서 제외됐습니다. 여기에는 단기 매출 전망의 정체와 사용자 매출에 가해지는 압력이 포함됩니다. 이런 전개는 특히 월마트와의 파트너십 같은 이니셔티브를 통해 텔라독의 매출과 마진을 안정화하려는 노력에 대한 면밀한 관찰을 한층 강화합니다. 해당 기사는 이번 지수 편출과, 텔라독의 밸류에이션에 대한 애널리스트들의 관점이 엇갈리는 상황을 고려할 때 투자자들이 텔라독의 향후 전망을 다시 평가하도록 촉구합니다.
텔레독 헬스, Inc.의 평균 주가 목표가가 20명의 애널리스트 추정치를 바탕으로 7.40달러에서 7.47달러로 상향되었습니다. 목표 범위는 주당 5달러~10.50달러입니다. 이번 업데이트된 목표가는 7월 6일 종가 기준 약 20% 하락 가능성을 시사합니다. TDOC에 대한 컨센서스 평가는 26명의 애널리스트 가운데 "보유(Hold)"로 유지됩니다.
B of A 증권은 텔레독 헬스(TDOC) 주당 목표가를 9.00달러에서 10.50달러로 상향했습니다. 이번 조정은 해당 애널리스트 리서치 기관이 회사 주식에 대해 더 긍정적인 전망을 내놓았다는 점을 반영합니다.
BofA 증권은 텔레독 헬스(TDOC.US)에 대해 매수(Buy) 의견을 재차 유지하며 목표주가를 10.5달러로 상향했습니다. 이번 조정은 원격의료 제공업체인 텔레독 헬스의 재무 전망과 시장 포지션에 대한 회사의 지속적인 신뢰를 반영합니다. 인상된 목표주가는 텔레독 헬스의 향후 주가 상승에 대한 기대를 나타냅니다.
텔레독 헬스 Inc의 미국 그룹 헬스 총괄인 Kelly Bliss는 2026년 7월 6일에 회사 주식 2,500주를 매도했습니다. 이번 거래는 지난 1년 동안 1건의 내부자 매수에 대해 33건의 내부자 매도가 있었던 패턴을 따릅니다. 텔레독 헬스 Inc는 GF Value 기준으로 현재 다소 고평가된 것으로 간주되며, 주가/GF Value 비율은 1.13입니다.
Teladoc Health (TDOC) is facing scrutiny due to stagnant sales, declining average revenue per user, and flat near-term sales estimates, despite a recent rally in its stock price. While a "narrative fair value" suggests the stock is overvalued at $9.20 compared to a $7.40 estimate, another perspective based on its P/S ratio (0.7x) indicates it might be undervalued relative to industry peers. Investors are left to weigh if the recent stock surge has already accounted for its future growth potential amidst mixed signals.
Teladoc Health, Inc.'s Chief Accounting Officer, Joseph Ronald Catapano, reported a sale of 653 common shares at $9.10 each on July 2, 2026, to cover the tax withholding obligation from the vesting of 2,083 restricted stock units (RSUs) on July 1, 2026. These RSUs were part of a larger 25,000-unit grant from October 2024. After these transactions, Catapano holds 12,267 Teladoc common shares directly, with 10,418 RSUs remaining outstanding.
Teladoc Health's Chief Accounting Officer, Joseph Ronald Catapano, sold 653 shares of company common stock for $5,942 to cover tax withholding obligations associated with RSU vestings. This transaction occurred on July 2, 2026, after 2,083 restricted stock units converted to common stock. Following the sale, Mr. Catapano directly holds 12,267 shares and 10,418 RSUs.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, sold 2,500 shares of Teladoc common stock at $9.50 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following this sale, Bliss directly holds 84,878 Teladoc shares.
Teladoc Health, Inc. (TDOC) has filed a Form 144 notice disclosing a proposed resale of 2,500 shares of common stock stemming from restricted stock vesting dated March 19, 2025. The filing also details three recent open-market sales by Kelly M. Bliss on June 2, June 29, and July 1, 2026, totaling 7,679, 2,500, and 2,500 shares respectively, with their associated proceeds. This Form 144 serves to provide public notice of these security transactions.
Teladoc Health (TDOC) is experiencing stagnant sales and falling average revenue per user, yet its stock has seen a significant rally. While one valuation narrative suggests TDOC is overvalued at $9.20 against a $7.40 fair value, another perspective notes its P/S ratio of 0.7x is well below industry averages, raising questions about whether the recent price surge has already accounted for future growth or if the market has overreacted negatively.
Teladoc Health (NYSE: TDOC) has granted 50,000 restricted stock units to David Packles, the new Head of Product for BetterHelp, effective July 1, 2026. These RSUs will vest one-third after one year, with the remainder vesting quarterly over the subsequent two years. This inducement award, made under NYSE Rule 303A.08, aims to incentivize and retain key leadership as Teladoc continues to invest in its virtual care offerings.
Teladoc Health, Inc. announced an inducement award to David Packles, the new Head of Product for BetterHelp. This award, effective July 1, 2026, consists of 50,000 restricted stock units that will vest over three years based on continued service. The award was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan, adhering to NYSE Rule 303A.08.
Teladoc Health, Inc. announced an inducement award to David Packles, the new Head of Product for BetterHelp. This award consists of restricted stock units covering 50,000 shares of Teladoc Health's common stock, vesting over approximately three years based on continued service. The grant was approved by the Compensation Committee and issued under the company's 2023 Employment Inducement Incentive Award Plan as per NYSE Rule 303A.08.
Truist Financial analysts have maintained "Hold" ratings on both Incyte (INCY) and Teladoc (TDOC). For Incyte, analyst Srikripa Devarakonda cited a Moderate Buy consensus with a slight downside from its average price target, while Jailendra Singh maintained a Hold rating for Teladoc, also noting a projected downside from its average price target. These ratings suggest analysts are neither significantly bullish nor bearish on the short-term prospects of these healthcare stocks.
Teladoc Health's stock has surged, nearing 52-week highs, despite underlying financial woes like declining revenue in its BetterHelp segment and persistent unprofitability. The company faces significant challenges, including a heavy debt load and a negative revenue growth rate for FY2025. Wall Street analysts maintain a cautious "Hold" rating with a median price target significantly below the current trading price, suggesting the rally is built on speculative interest rather than fundamental strength.
Teladoc Health's stock is up 28% year-to-date, outperforming the S&P 500, despite a 2% revenue decline in Q1 and continued unprofitability. The market is reacting positively to developments like increased insurance coverage for BetterHelp and international expansion, alongside AI initiatives that improve efficiency. However, the company still faces challenges including a competitive virtual therapy market and potential complexities with global expansion, making its stock risky despite recent progress.
Kelly Bliss, President, U.S. Group Health at Teladoc Health Inc (TDOC), sold 2,500 shares on July 1, 2026, reducing her holdings to 87,378 shares. Over the past year, she has sold 48,608 shares with no purchases, contributing to a pattern of 1 insider buy and 31 insider sells at Teladoc. The stock was trading at $9, making it fairly valued with a price-to-GF-Value ratio of 1.07.
Teladoc Health executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock for $22,500 at $9.00 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, and leaves her with 87,378 shares. The sale is considered routine and does not necessarily reflect a change in insider sentiment regarding the stock.
Teladoc Health, Inc. (TDOC) filed a Form 144, reporting sales of 10,179 shares in June 2026, totaling $79,817.73. The filing also detailed restricted stock vesting events in March and June 2025. These disclosures are routine for Form 144 filings and provide transparency on insider transactions.
Kelly Bliss, President of U.S. Group Health at Teladoc Health, recently sold 2,500 shares of the company's common stock for a total of $21,250, following a 10b5-1 trading plan. The sale occurred after the stock experienced a 10% gain over the past week and a 21% return year-to-date. Teladoc Health also announced new partnerships with Walmart and developments for its BetterHelp platform, alongside updated price targets from analysts.
Teladoc Health executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock at $8.50 per share on June 29, 2026, totaling $21,250. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Following the sale, Bliss directly holds 89,878 shares of Teladoc Health common stock.
Teladoc Health, Inc. (NYSE:TDOC) has been removed from the Russell Small Cap Comp Growth Benchmark, along with the Russell 2500 Growth, Russell 2000 Growth, and Russell 3000E Growth Benchmarks. This news follows several recent updates for the company, including making its services available through Walmart's Better Care Services platform and reporting its Q1 2026 earnings. The company provides virtual healthcare services through its Integrated Care and BetterHelp segments.
Teladoc Health (TDOC) has been removed from several Russell Growth indexes, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Composite Growth indexes, which could lead to mechanical selling by index-linked funds. While this may increase share price volatility, the underlying investment narrative still hinges on the company's ability to deepen its role in virtual chronic disease and mental health management despite unprofitability. The real risk for investors involves persistent reimbursement and margin pressure, with current forecasts projecting $2.6 billion revenue and $173.1 million earnings by 2029, suggesting a 12% downside to its current price based on a $7.40 fair value.
Teladoc (TDOC) shares recently gained 6.1% due to increased trading volume and investor optimism regarding the company's growth prospects and turnaround strategy. While the company is focusing on expanding its virtual care platform and improving efficiency, its upcoming earnings report is projected to show a loss per share and a decrease in revenue. The stock currently holds a Zacks Rank #3 (Hold), and its future strength depends on trends in earnings estimate revisions.
Teladoc Health, Inc. (NYSE: TDOC) has been removed from the Russell 2500 Growth Benchmark. This news follows a series of similar removals from other Russell indices, including the Russell Small Cap Comp Growth, Russell 2000 Growth, and Russell 3000E Growth Benchmarks, all announced on June 29, 2026. The virtual healthcare provider's stock performance and underlying metrics likely led to these changes in its index inclusions.
An affiliate of Teladoc Health (TDOC) has filed a Form 144 to sell 2,500 restricted shares that vested on June 1, 2025. The filing also indicates that 7,679 shares were sold in the prior three months for over $58,000. Fidelity Brokerage Services LLC is listed as the broker for the proposed resale.
Teladoc Health (TDOC) was recently removed from several Russell Growth indexes, including the Russell 2000 and 3000, which could lead to mechanical selling by index-linked funds and impact its institutional ownership. While this exit adds share price volatility, it doesn't alter Teladoc's core investment narrative centered on virtual care adoption and partnerships like Walmart Better Care Services. Investors are advised to consider the long-term implications of reimbursement and margin pressures on its path to profitability, as analysts have varying forecasts for its revenue and earnings.
The article presents financial data for Teladoc Health, Inc. (NYSE: TDOC), specifically focusing on its enterprise value to revenue forward metric. It appears to be a financial data point provided by TradingView, indicating a quantitative measure for the company over a specific period.
This article provides financial information for Teladoc Health, Inc. (NYSE: TDOC), specifically focusing on its forward price-to-sales ratio. It details the company's ticker symbol on the New York Stock Exchange and touches upon various data sources and copyright information related to the financial data presented.
This page provides financial actuals and estimates for Teladoc Health, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 1 Sh (BMFBOVESPA:T2DH34). Users can explore reported financial data and analyst estimates, comparing actual results with various estimates and visualizing trends over time across income statements, balance sheets, and cash flow statements. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Dr. Ethan Berke, the Chief Medical Officer of Teladoc Health, has been recognized as one of the "Most Influential Clinical Executives 2026" by Modern Healthcare. This recognition highlights his significant role and influence in the clinical executive field.
This article provides financial actuals and estimates for Teladoc Health, Inc. (NYSE:TDOC), including its current stock price, volatility, market capitalization, and analyst forecasts. It details the company's past earnings and revenue performance, future earnings report date, and an overview of its financial statements. The article also touches upon technical analysis ratings for TDOC stock.
This article provides an overview of Teladoc Health, Inc. (MUN:4LL) financial actuals and analyst estimates. It includes information on the company's stock ticker, future price forecasts, historical highs and lows, upcoming earnings reports, and key financial metrics such as earnings per share, revenue, net income, and EBITDA. The article also confirms that Teladoc Health, Inc. does not pay dividends and details its employee count.
Teladoc (TDOC) saw a 1.56% increase in its stock price, outperforming the S&P 500's loss, with a 16.69% rise over the past month. Despite a projected decrease in Q2 earnings per share and revenue, analysts' estimates for the company's annual performance show anticipated growth. Teladoc currently holds a Zacks Rank #3 (Hold).
Teladoc (TDOC) recently closed at $7.81, showing a 1.56% increase, outperforming the S&P 500's loss. Over the past month, TDOC stock climbed 16.69%, significantly exceeding the Medical sector's gain. Analysts anticipate Teladoc's upcoming earnings per share to be -$0.24, with revenue projected at $614.69 million for the quarter.
This article from Investing.com announces a Form 13G filing for Teladoc Health pertaining to June 22. It provides no further details beyond this announcement, merely stating the filing has occurred. The rest of the content includes market data and news headlines unrelated to the Form 13G.
Voss entities and Travis Cocke have reported a beneficial ownership of 9.03 million shares in Teladoc Health (TDOC), representing approximately 5.0% of the company's outstanding shares. This disclosure, made via a SCHEDULE 13G SEC filing, details holdings across Voss Value Master Fund, Voss Value-Oriented Special Situations Fund, Voss Advisors GP, Voss Capital, and Travis W. Cocke directly. The reported holdings include 700,000 shares underlying currently exercisable call options and are based on 180,513,087 shares outstanding as of April 23, 2026.
Teladoc Health (TDOC) has extended its rally to a seventh consecutive session. The stock closed up 2.7% at $10.66 today, bringing its seven-day gain to 12% and its year-to-date performance to +28%. This positive movement follows a period of significant losses, as the stock had previously plummeted 79% in 2022 and 22% in 2023.
Teladoc Health, Inc. (TDOC) has been upgraded from a "Sell" to a "Hold" rating due to slight strategic pivots aimed at new growth avenues, despite stagnant revenues. The company's Q1 2026 results showed a 2% year-over-year revenue decrease, though it remains EBITDA and cash flow positive. Key initiatives like a Walmart partnership and BetterHelp's insurance rollout are being watched as important tests for boosting utilization and top-line performance.
Teladoc Health Inc (TDOC) has an current earnings forecast score of 6.67, ranking 52 out of 76 in its industry, with an average price target of $8.50. Analysts largely recommend a "hold" for the stock, with 26 analysts contributing to the rating. The company's expected revenue for the next quarter is $614.91M, and its EPS for the previous quarter was -$0.14, with the next quarter's EPS projected at -$0.25.
Teladoc Health is facing conflicting signals, with analysts projecting a 26.32% year-over-year earnings decline for its upcoming report, yet recent estimate revisions suggest healthier near-term business conditions and improved profitability expectations. This combination suggests that while short-term earnings remain a risk, the focus for Teladoc's investment narrative is shifting towards evidence of margin progress and successful partnerships like the one with Walmart's Better Care Services platform. The stock's fair value is estimated at $7.12, indicating a 3% downside from its current price, though some analysts are far more optimistic about its long-term potential.
Teladoc Health (TDOC) is facing conflicting signals, with analysts projecting a 26.32% year-over-year earnings decline for its upcoming report, yet recent estimate revisions indicate healthier near-term business conditions and improving profitability expectations. The company's investment narrative relies on virtual care becoming core to patient management and Teladoc achieving sustainable profitability, with recent partnerships like the one with Walmart's Better Care Services platform aiming to expand consumer access and visit volumes. Despite these promising developments, investors should be aware of a less obvious risk concerning BetterHelp’s shift toward lower-margin insurance-based revenue.
Analysts are projecting a 26.32% year-over-year earnings decline for Teladoc Health (TDOC) ahead of its upcoming report, yet recent estimate revisions suggest improving near-term business conditions. This conflicting outlook, coupled with strategic partnerships like the one with Walmart, highlights the importance of observing margin progress as a key catalyst. Despite an anticipated earnings decline, an analysis forecasts Teladoc reaching $2.6 billion in revenue and $164.1 million in earnings by 2029, suggesting a potential fair value of $7.12.
Teladoc Health (TDOC) stock has significantly underperformed the broader market, trading near its 52-week low due to persistent revenue growth challenges and intense competition in the telehealth sector. Despite recent earnings beats, cautious forward guidance and concerns over declining user engagement are weighing on investor sentiment. The company's debt profile and ongoing goodwill impairment charges, stemming from past acquisitions, also contribute to investor apprehension.
Teladoc Health, Inc. CEO Charles DiVita III exercised restricted and performance stock units, acquiring 42,802 common shares. He subsequently sold 18,074 shares at $6.942 each to cover tax withholding obligations related to the vesting of these awards. After these transactions, DiVita directly holds 414,622 shares of Teladoc common stock, indicating a routine compensation event rather than a discretionary sale for liquidity.
Teladoc Health (NYSE:TDOC) stock surged 69% after InvestingPro's Fair Value analysis identified it as significantly undervalued in February 2026. The analysis, which calculates intrinsic value through multiple valuation methodologies, accurately predicted the stock's remarkable return from $4.68 to $7.34. The company's rally was driven by improved fundamentals and a new partnership with Walmart, and InvestingPro's current analysis suggests further upside potential.
